Research Focus AAVogen specializes in gene therapeutics for muscle wasting diseases, presenting opportunities to collaborate with healthcare providers for patient treatment solutions.
Funding Momentum With a recent $2.3 million financing round and a history of NIH grants, AAVogen's funding momentum signals potential investment or partnership opportunities for growth.
Market Expansion In a competitive landscape with companies like Adverum Biotechnologies and Apellis Pharmaceuticals, AAVogen's unique approach to gene therapeutics opens doors for market expansion and differentiation.
Tech Stack Innovation AAVogen utilizes advanced technologies like HTTP/3 and OpenResty, showcasing a commitment to innovation that can attract tech-savvy partners for joint research or development projects.
Employee Engagement Despite having 2-10 employees, AAVogen's focused team size provides a close-knit environment that appeals to potential collaborators looking for agile and efficient partnerships.
$10M$50M
$100M$1B
$100M$1B
$10M
$10M$50M
$10MAAVogen uses 8 technology products and services including WordPress, jQuery, HTTP/3, and more. Explore AAVogen's tech stack below.
| AAVogen Email Formats | Percentage |
| FirLast@aavogen.com | 50% |
| FirLast@aavogen.com | 50% |
Biotechnology ResearchMaryland, United States2-10 Employees
Biotech startup that develops gene therapeutics for muscle wasting diseases. This includes inclusion body myositis, muscular dystrophies, peripheral nerve damage and more. At AAVogen, we make you stronger!
Company Overview
Funding & FinancialsAAVogen has raised a total of $275K of funding over 7 rounds. Their latest funding round was raised on Aug 01, 2023 in the amount of $275K.
Funding & FinancialsAAVogen has raised a total of $275K of funding over 7 rounds. Their latest funding round was raised on Aug 01, 2023 in the amount of $275K.
1-888-653-2347 
support@leadiq.com